Zusammenfassung
Das duktale Adenokarzinom des Pankreas ist besonders durch eine schlechte Prognose gekennzeichnet, die unter anderem durch eine frühe Inoperabilität der Tumoren bedingt ist. Auch bei unter potenziell kurativem Aspekt operierten Patienten kommt es häufig zu Lokalrezidiven mit entsprechend schlechterem Verlauf der Erkrankung. Zur besseren Einschätzung ist sowohl eine standardisierte Aufarbeitung von Pankreaskopfresektaten als auch eine strenge Anwendung der R-Klassifikation zu fordern. Bezüglich einer Abschätzung des Rezidivrisikos sollte ein vergleichbares Konzept, wie für das kolorektale Karzinom, mit Angabe des minimalen Abstands zum zirkumferenziellen Resektionsrand prospektiv evaluiert werden.
Abstract
The ductal adenocarcinoma of the pancreas is characterised by a very poor prognosis due to an early inoperability of the tumours. Even if operated under curative aspects, local recurrence of the disease is quite frequent with corresponding poorer prognosis. For a better assessment, standardised protocols for the pathohistological processing of resection specimens of the pancreas are needed urgently as well as a strict adherence to the R classification. In order to establish a reliable marker for the risk of recurrence, the smallest distance to the circumferential resection margin should be indicated in comparison to the circumferential resection margin (CRM) concept in colorectal carcinoma.
Schlüsselwörter
duktales Adenokarzinom des Pankreas - Pankreaschirurgie - R-Klassifikation - Prognosefaktor
Key words
ductal adenocarcinoma of the pancreas - pancreas surgery - R classification - prognostic factor
Literatur
-
1
Tannapfel A.
Pancreatic cancer. Molecular and surgical pathology.
Pathologe.
2010;
31 (Suppl 2)
225-228
-
2
Seufferlein T, Adler G.
The S 3 guideline exocrine pancreatic cancer.
Med Klin.
2009;
104
869-874
-
3
Adler G, Seufferlein T, Bischoff S C et al.
S3-Guidelines „Exocrine pancreatic cancer” 2007.
Z Gastroenterol.
2007;
45
487-523
-
4
Fietkau R, Heinemann V, Oettle H et al.
New data on pancreatic cancer.
Onkologie.
2010;
33 (Suppl 4)
31-35
-
5
Belyaev O, Herzog T, Chromik A et al.
Pankreaschirurgie – Der Chirurg als entscheidender Prognosefaktor.
Gastroenterologe.
2006;
1
8
-
6
Jones S, Zhang X, Parsons D W et al.
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.
Science.
2008;
321
1801-1806
-
7 Wittekind C, Meyer H J. TNM Klassifikation maligner Tumore. Weinheim: Wiley-Blackwell; 2010
-
8
Raut C P, Tseng J F, Sun C C et al.
Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Ann Surg.
2007;
246
52-60
-
9
Verbeke C S.
Resection margins and R 1 rates in pancreatic cancer – are we there yet?.
Histopathology.
2008;
52
787-796
-
10
Esposito I, Kleeff J, Bergmann F et al.
Most pancreatic cancer resections are R 1 resections.
Ann Surg Oncol.
2008;
15
1651-1660
-
11
Neoptolemos J P, Stocken D D, Bassi C et al.
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
JAMA.
2010;
304
1073-1081
-
12
Jamieson N B, Foulis A K, Oien K A et al.
Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma.
Ann Surg.
2010;
251
1003-1010
-
13
Campbell F, Smith R A, Whelan P et al.
Classification of R 1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin.
Histopathology.
2009;
55
277-283
-
14 Bosman F T, Carneiro F, Hruban R H eds.. WHO Classification of Tumours of the Digestive System. 4 ed. World Health Orgn; 2010
-
15
Wittekind C, Compton C, Quirke P et al.
A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status.
Cancer.
2009;
115
3483-3488
-
16
Chang D K, Johns A L, Merrett N D et al.
Margin clearance and outcome in resected pancreatic cancer.
J Clin Oncol.
2009;
27
2855-2862
-
17
Seelig M H, Janot M, Chromik A M et al.
Redo-surgery following curative resection of pancreatic carcinoma: the difference between true and suspected recurrence.
Dig Surg.
2009;
26
222-228
-
18
Gaedcke J, Gunawan B, Grade M et al.
The mesopancreas is the primary site for R 1 resection in pancreatic head cancer: relevance for clinical trials.
Langenbecks Arch Surg.
2010;
395
451-458
-
19
Hernandez J, Mullinax J, Clark W et al.
Survival after pancreaticoduodenectomy is not improved by extending resections to achieve negative margins.
Ann Surg.
2009;
250
76-80
-
20
Menon K V, Gomez D, Smith A M et al.
Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP).
HPB.
2009;
11
18-24
-
21 National Comprehensive Cancer Network (NCCN) .Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma. 2008 http://www.nccn.org/professionals/physician_gls/default.asp
-
22
McClaine R J, Lowy A M, Sussman J J et al.
Neoadjuvant therapy may lead to successful surgical resection and improved survival in patients with borderline resectable pancreatic cancer.
HPB.
2010;
12
73-79
Dr. Johanna Munding
Institut für Pathologie, Ruhr-Universität Bochum
Bergmannsheil Bochum
44789 Bochum
Phone: ++ 49/2 34/3 02 49 61
Fax: ++ 49/2 34/3 02 48 09
Email: johanna.munding@rub.de
